Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) PT at $203.57

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have received an average recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $206.1538.

Several analysts have recently weighed in on the stock. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, December 15th. Robert W. Baird set a $193.00 price target on shares of Charles River Laboratories International in a research note on Thursday, February 19th. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Evercore upped their price objective on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, TD Cowen dropped their price objective on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, February 20th.

Charles River Laboratories International Trading Up 0.3%

CRL opened at $153.52 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. Charles River Laboratories International has a one year low of $91.86 and a one year high of $228.88. The company has a market cap of $7.56 billion, a P/E ratio of -51.86, a PEG ratio of 2.62 and a beta of 1.64. The business’s 50-day simple moving average is $185.42 and its 200-day simple moving average is $180.56.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The firm’s revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities research analysts expect that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Tema Etfs LLC purchased a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $26,000. Rothschild Investment LLC grew its position in shares of Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares during the last quarter. Neo Ivy Capital Management purchased a new position in shares of Charles River Laboratories International during the second quarter worth approximately $29,000. Atlantic Union Bankshares Corp acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at $31,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Charles River Laboratories International in the 4th quarter valued at $42,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.